Cybin Inc. (CYBN)
(Real Time Quote from BATS)
$9.04 USD
-0.49 (-5.14%)
Updated Dec 26, 2024 03:48 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CYBN 9.04 -0.49(-5.14%)
Will CYBN be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for CYBN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CYBN
What Makes Cybin Inc. (CYBN) a New Buy Stock
Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround
CYBN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cybin (CYBN) Begins Phase II Study on Anxiety Drug, Stock Up
Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?
Brian's Big Idea on Biotech
Other News for CYBN
Cybin Reveals Promising Results in Depression Treatment
Cybin to Discuss Breakthrough Treatments at Fireside Chat
TANG CAPITAL MANAGEMENT LLC Increases Stake in Cybin Inc
Cybin Inc. Advances in Mental Health Treatments
Rising High: Numinus Wellness to sell five Utah clinics for $3.53M